These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25443349)

  • 1. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.
    Kumar S; Jacobson IM
    J Hepatol; 2014 Nov; 61(1 Suppl):S91-7. PubMed ID: 25443349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Omata M; Nishiguchi S; Ueno Y; Mochizuki H; Izumi N; Ikeda F; Toyoda H; Yokosuka O; Nirei K; Genda T; Umemura T; Takehara T; Sakamoto N; Nishigaki Y; Nakane K; Toda N; Ide T; Yanase M; Hino K; Gao B; Garrison KL; Dvory-Sobol H; Ishizaki A; Omote M; Brainard D; Knox S; Symonds WT; McHutchison JG; Yatsuhashi H; Mizokami M
    J Viral Hepat; 2014 Nov; 21(11):762-8. PubMed ID: 25196837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rapid evolution of treatment strategies for hepatitis C.
    Muir AJ
    Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ
    Antiviral Res; 2014 Jul; 107():119-24. PubMed ID: 24792751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
    Lawitz EJ; Rodriguez-Torres M; Denning J; Mathias A; Mo H; Gao B; Cornpropst MT; Berrey MM; Symonds WT
    J Viral Hepat; 2013 Oct; 20(10):699-707. PubMed ID: 24010644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir as backbone of interferon free treatments.
    Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir for the treatment of hepatitis C virus.
    Asselah T
    Expert Opin Pharmacother; 2014 Jan; 15(1):121-30. PubMed ID: 24289735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 11. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No compelling reason to adopt new antivirals whenever it is reasonable to wait.
    Prescrire Int; 2015 Jan; 24(156):8. PubMed ID: 25729821
    [No Abstract]   [Full Text] [Related]  

  • 13. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.
    Berden FA; Kievit W; Baak LC; Bakker CM; Beuers U; Boucher CA; Brouwer JT; Burger DM; van Erpecum KJ; van Hoek B; Hoepelman AI; Honkoop P; Kerbert-Dreteler MJ; de Knegt RJ; Koek GH; van Nieuwkerk CM; van Soest H; Tan AC; Vrolijk JM; Drenth JP
    Neth J Med; 2014 Oct; 72(8):388-400. PubMed ID: 25387551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment: an incipient therapeutic revolution.
    deLemos AS; Chung RT
    Trends Mol Med; 2014 Jun; 20(6):315-21. PubMed ID: 24636306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal therapy of genotype-2 chronic hepatitis C: what's new?
    Bourlière M; Benali S; Ansaldi C; Le Folgoc G; Riso A; Lecomte L
    Liver Int; 2015 Jan; 35 Suppl 1():21-6. PubMed ID: 25529084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
    Peter J; Nelson DR
    Liver Int; 2015 Jan; 35 Suppl 1():65-70. PubMed ID: 25529089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis C genotype 1.
    Foster GR; De Silva S
    Curr Opin Infect Dis; 2014 Dec; 27(6):535-9. PubMed ID: 25304394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series.
    Cornella SL; Stine JG; Kelly V; Caldwell SH; Shah NL
    Postgrad Med; 2015 May; 127(4):413-7. PubMed ID: 25746436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir: first global approval.
    Keating GM; Vaidya A
    Drugs; 2014 Feb; 74(2):273-82. PubMed ID: 24442794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.